Lexicon Pharmaceuticals has been upgraded to a Buy rating due to several upcoming catalysts in its drug pipeline. The company plans to resubmit its New Drug Application (NDA) for ZYNQUISTA in treating Type 1 Diabetes by Q4 2026, pending safety data from the STENO1 study. Additionally, top-line results from the phase 3 SONATA-HCM trial for sotagliflozin in hypertrophic cardiomyopathy are expected in Q1 2027. A partnership with Novo Nordisk on LX9851 for obesity could bring up to $1 billion in milestone payments, though financial risks remain. These developments position Lexicon as a promising biotech investment opportunity.
Lexicon Pharmaceuticals' pipeline developments come as context from Pluang's Health sector data. For readers following health stocks, here is Pluang's market snapshot as of Oct 01, 2026 01:11 WIB: out of 100 priced US health stocks, 48 rose and 52 fell. Heron Therapeutics Inc (HRTX) gained 5.58% to USD 0.33 with a typical hold time of 35 days, contrasting with Moderna, Inc. (MRNA) which dropped 5.52% to USD 192.23 and a longer hold time of 59 days. Hims and Hers Health Inc (HIMS) rose 5.47% to USD 30.27, showing strong buy interest at 99% buy order activity.
Cullinan Therapeutics announced promising Phase 1b/2a trial results for velinotamig, a BCMAxCD3 T cell engager, in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE). Among nine evaluable patients, eight showed significant...
CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treate...
At the 13th annual Muhammad Ali Humanitarian Awards in Louisville, Colin Kaepernick was honored as Humanitarian of the Year for his activism and entrepreneurship, including founding literacy platform Lumi and Know Your Rights Camp. The event also rec...
Cabaletta Bio announced Phase 1/2 clinical data for rese-cel, a CAR T cell therapy targeting autoimmune diseases, showing durable benefits without immunomodulators across dermatomyositis, lupus nephritis, and systemic sclerosis patients. All dermatom...
Parex Resources reported third-quarter results showing wider discounts and increased costs mainly due to one-time acquisition and optimization expenses. Despite these challenges, the company remains larger and more productive after recent acquisition...
